Trials / Completed
CompletedNCT01061359
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,981 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events. (E=Epirubicin; C =Cyclophosphamide)
Detailed description
Postmarketing surveillance study. Non-Probability Sample
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin: Observational Study | Observational: Chemotherapy |
Timeline
- Start date
- 1999-01-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2010-02-03
- Last updated
- 2010-12-29
- Results posted
- 2010-11-18
Source: ClinicalTrials.gov record NCT01061359. Inclusion in this directory is not an endorsement.